Kura肿瘤学 KURA 深 沪
等待开盘 09-17 09:30:00 美东时间
8.35
+0.140
+1.71%
华盛通- 最 高8.45
- 今 开8.22
- 成交量 132.41万股
- 最 低 8.22
- 昨 收 8.21
- 总市值 7.25亿
- 52周最高 19.935
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.41
- 委 比 22.64%
- 总股本 8679.72万
- 历史最高 43.00
- 量 比 0.66
- 振 幅 2.80%
- 历史最低 2.50
- 每 手 1
- 风险率 4.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology Showcases Preclinical Data Targeting Resistance Pathways, Highlights KO-2806 Combo Potential Ahead Of ESMO 2025
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)Preliminary clinical data and
今天 04:02
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
Kura Oncology hosted an analyst/investor event to highlight the potential of KO-2806 (darlifarnib), a next-generation farnesyl transferase inhibitor (FTI), in combination with PI3Kα inhibitors, KRAS inhibitors, and antiangiogenic tyrosine kinase inhibitors (TKIs). The event showcased preclinical data demonstrating KO-2806's ability to enhance anti-tumor activity, overcome resistance mechanisms, and re-sensitize tumors to targeted therapies. Preli...
09-16 20:01
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
09-10 05:06
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.
09-05 03:17
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
Kura Oncology will host two virtual events to highlight its FTI program. The first event on September 16 will focus on preclinical data combining FTIs with targeted therapies, while the second event on October 18 will discuss clinical data from ESMO Congress 2025, including initial results from KO-2806, Kura's next-generation FTI. These events aim to showcase Kura's leadership in addressing treatment challenges in cancer through precision medicin...
09-03 12:02
Kura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology announced that its management will participate in three investor conferences in September: Cantor Global Health Conference on September 4, H.C. Wainwright Global Investment Conference on September 8, and Morgan Stanley Global Healthcare Conference on September 10. Live audio webcasts will be available on the company's website. Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer, deve...
08-28 11:30
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on F...
08-15 22:14
JMP Securities Maintains Market Outperform on Kura Oncology, Lowers Price Target to $24
JMP Securities analyst Reni J. Benjamin maintains Kura Oncology (NASDAQ:KURA) with a Market Outperform and lowers the price target from $28 to $24.
08-11 20:16
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
